Browsing by Author "Linardou, H."
Now showing items 1-5 of 5
-
Article
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group study
Skarlos, Dimosthenis V.; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Gennatas, Constantinos; Beer, M.; Mylonakis, N.; Makrantonakis, P.; Klouvas, G. D.; Karpathios, S.; Linardou, H.; Konstantaras, C.; Fountzilas, George (1996)We compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 ...
-
Article
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
Fountzilas, George; Dafni, U.; Bobos, M.; Kotoula, V.; Batistatou, Anna; Xanthakis, I.; Papadimitriou, C.; Kostopoulos, I.; Koletsa, T.; Tsolaki, E.; Televantou, D.; Timotheadou, E.; Koutras, A. K.; Klouvas, G. D.; Samantas, E.; Pisanidis, N.; Karanikiotis, C.; Sfakianaki, I.; Pavlidis, Nicholas; Gogas, H.; Linardou, H.; Kalogeras, K. T.; Pectasides, Dimitrios; Dimopoulos, M. A. (2013)Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...
-
Article
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Pectasides, Dimitrios; Kalogera-Fountzila, Anna; Skarlos, Dimosthenis V.; Kalofonos, H. P.; Papadimitriou, C.; Bafaloukos, Dimitrios; Lambropoulos, S.; Papadopoulos, S.; Kourea, H.; Markopoulos, C.; Linardou, H.; Mavroudis, D.; Briassoulis, E. Ch; Pavlidis, Nicholas; Razi, E. D.; Kosmidis, Paraskevas A.; Gogas, H. (2005)Paclitaxel (TaxolR) and carboplatin are an effective combination regimen for treating advanced breast cancer. Gefitinib (IRESSA) is the first epidermal growth factor receptor tyrosine kinase inhibitor to be approved for ...
-
Article
Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG)
Pentheroudakis, George; Kotoula, V.; Eleftheraki, A. G.; Tsolaki, E.; Wirtz, R. M.; Kalogeras, K. T.; Batistatou, Anna; Bobos, M.; Dimopoulos, M. A.; Timotheadou, E.; Gogas, H.; Christodoulou, C.; Papadopoulou, K.; Efstratiou, I.; Scopa, C. D.; Papaspirou, I.; Vlachodimitropoulos, D.; Linardou, H.; Samantas, E.; Pectasides, Dimitrios; Pavlidis, Nicholas; Fountzilas, George (2013)Background:Discrepant data have been published on the incidence and prognostic significance of ESR1 gene amplification in early breast cancer.Patients and Methods:Formalin-fixed paraffin-embedded tumor blocks were collected ...
-
Article
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A hellenic cooperative oncology group (HECOG) study
Psyrri, A.; Kalogeras, K. T.; Kronenwett, R.; Wirtz, R. M.; Batistatou, Anna; Bournakis, E.; Timotheadou, E.; Gogas, H.; Aravantinos, Gerasimos; Christodoulou, C.; Makatsoris, T.; Linardou, H.; Pectasides, Dimitrios; Pavlidis, Nicholas; Economopoulos, T.; Fountzilas, George (2012)Background: The ubiquitin-proteasome system (UPS) plays a pivotal role in tumorigenesis. Components of the UPS have recently been implicated in breast cancer progression. In the present study, we sought to explore the ...